Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Novavax has not received an official response from the FDA related to the status of the BLA. The BLA was based on data from a phase III study, which showed the vaccine was safe and effective for ...

Shares of Novavax (NVAX) are under pressure on Thursday ... composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” ...

When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's composition. He said Novavax's single antigen approach "has never worked" for ...